SUBKLEWE CV 2016 M4 - EFI...

Marion Subklewe, M.D. Curriculum vitae

Univ. Professor Dr. med. Marion Subklewe

Curriculum vitae

Hospital address: Laboratory address: Klinikum -‐ University of Munich Gene Center Munich Medical Department III Laboratory for Translational Hematology / Oncology Cancer Immunology Marchioninistrasse 15 Feodor-‐Lynen Straße 25 81377 München 81377 München Germany Germany phone: +49 89 4400 7 3133 phone: +49 89 2180 76875 [email protected]‐muenchen.de [email protected] Personal Data Date and Place of birth: 26th of July 1967 in Pasadena / California Family Status: married, 4 children (*1999, *2002, *2004,*2006) Professional Experience Since 2014 Professor for Internal Medicine with focus on Cellular Immunotherapy Medical Department III, Hematology / Oncology, Klinikum – University of Munich since 2012 Head of the Clinical Cooperation Group „Immunotherapy“

Helmholtz Zentrum Munich since 2009 Head of Flow cytometry

Laboratory of Leukemia Diagnostics, Klinikum -‐ University of Munich, Medical Department III, Hematology / Oncology, Prof. Dr. W. Hiddemann

since 2009 Attending Physician for Hematology / Oncology, Klinikum -‐ University of Munich,

Department of Medicine III, Hematology / Oncology, Prof. Dr. W. Hiddemann 2008 -‐ 2009 Clinical Fellow Hematology / Oncology, Klinikum -‐ University of Munich,

Department of Medicine III, Hematology / Oncology, Prof. Dr. W. Hiddemann 2000 -‐ 2007 Clinical Fellow Hematology / Oncology, Charité – Campus Virchow Klinikum,

Medical Department III, Hematology / Oncology -‐ Prof. Dr. B. Dörken 1996 -‐ 2000 Postdoctoral Fellow, DFG-‐Scholarship, Cure for Lymphoma Fellow Rockefeller University, New York -‐ Prof. Dr. R. M. Steinman 1995 -‐ 1996 Residency Internal Medicine, University Hospital Tübingen,

Medical Department II – Hematology / Oncology / Rheumatology -‐ Prof. Dr. L. Kanz 1994 -‐ 1995 Internship, University Hospital Freiburg,

Medical Department II – Hematology / Oncology, Prof. Dr. R. Mertelsmann


Education 2012 W2-‐Professor for Internal Medicine with focus on Cellular Immunotherapy 2007 „Habilitation“ in Internal Medicine at the Charité, Berlin 2007 Board Certification Hematology / Oncology 2005 Board Certification Internal Medicine 1995 Medical Dissertation at the University of Cologne, Department of Internal Medicine,

Hematology / Oncology (Prof. Dr. V. Diehl) 1988 -‐ 1993 Study of Medicine at the University of Cologne 1986 -‐ 1988 Study of Medicine at the RWTH Aachen Honors and Awards

• M4-‐Award 2015: Startup support for the development of a novel multispecific antibody derivative

• ASH Abstract Achievement Award 2015: Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE Antibody Construct (AMG 330) Mediated Cytotoxicity

• DGHO-‐Poster Prize 2014: Addition of CD200 and Omission of sIgM Improves the Scoring System for the Diagnosis of CLL

• Selection for the ASH Highlights 2013: Evaluation of CD33 expression and functional analysis of the CD33/CD3 bispecific antibody AMG 330 activity in primary AML samples

• Therese von Bayern-‐Award 2012

• ASH Abstract Achievement Award 2011: A Combined Score of Minimal Residual Disease (MRD) Assessment by Flow Cytometry, Cytogenetic and Molecular Markers As Well As Age Predicts Outcome and Can Potentially Guide MRD-‐Based Therapy in Acute Myeloid Leukemia

• ASH Abstract Achievement Award 2011: Dendritic Cells Matured with a TLR7/8 Agonist Induce T Helper 1 Cell Polarization, Activate NK Cells and Are Thus Highly Suitable for Application in Cancer Immunotherapy

• Best Lecturer at the faculty of Medicine at the LMU 2011

• Rahel-‐Hirsch Scholarship 2005 – 2007 at the Charité („Habilitations-‐Scholarship“)

• Cure for Lymphoma Foundation Fellow 1999 – 2000

• Postdoctoral Scholarship of the Deutsche Forschungsgemeinschaft 1996 – 1999


Additional Functions

• Principal Investigator and Sponsor delegated Person of a prospective Phase I/II I-‐IT “Active immunotherapy of patients with AML using autologous dendritic cells transfected with RNA encoding leukemia-‐associated antigens”

• Principal Investigator of a Phase I Study „A Phase 1 First-‐in-‐Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Acute Myeloid Leukemia“

• Principle Investigator in multiple Phase I trials (CAR T, T-‐cell recruiting antibodies), Principle Investigator in multiple Phase II/III trials in leukemia and lymphoma (GMALL, GLSG, DSHNHL)

• Protocol committee AML Cooperative Group (AML-‐CG)

• Member of the Organizing Committee of the International Symposium “Acute Leukemias” 2011; 2013; 2015; 2017

• Certification (2011) and Akkreditation Flow Cytometry (2012) within the Laboratory of Leukemia Diagnostics

• Collaborative Research Activities – Bavarian Immunotherapy Network, Helmholtz Alliance for Immunotherapy, Deutsches Konsortium für Translationale Krebsforschung, Munich Immunotherapy Consortium (MITC), Elitenetzwerk Bayern International Graduate School “Immunotargeting of Cancer”, SFB1243 “Cancer Evolution”, Else-‐Kröner Fresenius Forschungskolleg “Cancer Immunotherapy”

• Grant Reviews -‐ Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; José-‐Carreras Stiftung; Wilhelm Sander Stiftung; Cancer Research UK; Leukemia and Lymphoma; OeGHO, Dutch Cancer Society, Wordwide Cancer Research

• Manuscript Reviews – Blood, Leukemia, Lancet Hematology, NEJM, PlosOne, J International Immunology, Journal of Hematology & Oncology; Haematologica; British Journal of Hematology

• Membership -‐ Bund deutscher Internisten (BdI); European Association for Hematology (EHA); American Society for Hematology (ASH); Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO); Society for Immunotherapy of Cancer (SITC)

• Member of the “Research committee (Forschungskommission)” Klinikum der Universität München, member of several Thesis Advisory Committees


Publications

1. Ponce LP, Fenn NC, Moritz N, Krupka C, Kozik JH, Lauber K, Subklewe M, Hopfner KP.: SIRPα-‐antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells. Oncotarget. 2017 Jan 4. [Epub ahead of print], IF 5.0

2. Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S.: Response to Rituximab Induction Is a Predictive Marker in B-‐Cell Post-‐Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-‐CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. J Clin Oncol. 2016 Dec 19:JCO2016693564. [Epub ahead of print], IF 20.982

3. Bücklein V, Adunka T, Mendler A, Issels R, Subklewe M, Schmollinger J, Noessner E: Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-‐tissue sarcoma patients. Oncoimmunology. 2016 Apr 29;5(7):e1178421., IF 7.6

4. Schuh E, Berer K, Mulazzani M, Feil K, Meinl I, Lahm H, Krane M, Lange R, Pfannes K, Subklewe M, Gürkov R, Bradl M, Hohlfeld R, Kümpfel T, Meinl E, Krumbholz M: Features of Human CD3+CD20+ T cells: J Immunol. 2016 Aug 15;197(4):1111-‐7., IF 5.2

5. Metzeler KH, Herold T, Rothenberg-‐Thurley M, Amler S, Sauerland MC, Goerlich D, Schneider S, Konstandin NP, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif PA, Fiegl M, Subklewe M, Bohlander SK, Krug U, Faldum A, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K: Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016 Aug 4;128(5):686-‐98., IF 11.8

6. Herhaus P, Habringer S, Philipp-‐Abbrederis K, Vag T, Gerngross C, Schottelius M, Slotta-‐Huspenina J, Steiger K, Altmann T, Weisser T, Steidle S, Schick M, Jacobs L, Slawska J, Mueller-‐Thomas C, Verbeek M, Subklewe M, Peschel C, Wester HJ, Schwaiger M, Goetze K, Keller U: Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. Haematologica 2016 May 12, Epub ahead of print, IF 6.7

7. Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmüller G, Subklewe M: Blockade of the PD-‐1/PD-‐L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-‐cell-‐induced immune escape mechanism. Haematologica. 2016 Aug;101(8):932-‐40. IF 12.1

8. Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S: Immunotherapy in Tumors. Dtsch Arztebl Int 2015 Nov 27; 112(48):809-‐15, IF 3.6


9. Köhnke T, Krupka C, Tischer J, Knösel T, Subklewe M: Increase of PD-‐L1 expressing B-‐precursor ALL cells in a patient resistant to the CD19/CD3-‐bispecific T cell engager antibody blinatumomab. J Hematol Oncol. 2015 Oct 8;8(1):111, IF 6.3

10. Lichtenegger FS, Kondla I, Krempasky M, Weber AL, Herold T, Krupka C, Spiekermann K, Schneider S, Büchner T, Berdel WE, Wörmann BJ, Hiddemann W, Subklewe M: RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-‐related pathways and relapse-‐free survival of patients with AML. Cancer Immunol Immunother. 2015 Dec;64(12):1505-‐15. IF 4.8

11. Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, Hiddemann W, Subklewe M: T cells are functionally not impaired in AML: increased PD-‐1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol. 2015 Jul 30;8:93, IF 6.3

12. Lichtenegger FS, Krupka C, Köhnke T, Subklewe M: Immunotherapy for Acute Myeloid Leukemia. Semin Hematol. 2015 Jul;52(3):207-‐14; IF 4.4

13. Dreyling M, Subklewe M: Bendamustine and the immune system: a wolf in sheep´s clothing ? Leuk Lymphoma 2015 Apr; 56(4) 837-‐8. IF 2.9

14. Zugmaier G., Kliniger M, Schmidt M, Subklewe M: Clinical overview of anti-‐CD19BiTE and ex vivo data from anti-‐CD33 BiTE as examples for retargeting T cells in hematologic malignancies. Mol Immunol 2015 Apr 13. IF 3.4

15. Vick B, Rothenberg M, Sandhöfer N, Carlet M, Finkenzeller C, Krupka C, Grunert M, Trumpp A, Corbacioglu S, Ebinger M, André MC, Hiddemann W, Schneider S, Subklewe M, Metzeler KH, Spiekermann K, Jeremias I: An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging. PLoS One. 2015 Mar 20; 10(3). IF 3.5

16. Köhnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M, Bohlander SK, Kakadia PM, Schneider S, Dufour A, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Spiekermann K, Subklewe M: Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. Leukemia 2015 Feb; 29(2):377-‐86. IF 12.1

17. Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Fröhling S, Klein HG, Hiddemann W, Jeremias I, Spiekermann K.: Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-‐rearranged acute myeloid leukemia. Leukemia. 2015 Apr, 29 (4):828-‐38. IF 12.1

18. Subklewe M, Geiger C, Lichtenegger FS, Javorovic M, Kvalheim G, Schendel DJ, Bigalke I: New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunol Immunother. 2014 Oct, 63(10):1093-‐103. IF 4.8


19. Lichtenegger FS, Lorenz R, Gellhaus K, Hiddemann W, Beck B, Subklewe M: Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML. Leuk Res. 2014 Aug; 38(8); 964-‐9. IF 2.6

20. Witter K, Reibke R, Subklewe M, Zahn R, Kauke T, Spiekermann K, Spannagl M, Tischer J, Hiddemann W, Dick A: Combination of Complement-‐Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity. Bone Marrow Res. 2014; 2014:541345.

21. Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander SK, Subklewe M, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Hiddemann W, Spiekermann K: Molecular response assessment by quantitative real-‐time polymerase chain reaction after induction therapy in NPM1-‐mutated patients identifies those at high risk of relapse. Haematologica.2014. Aug; 99(8):1317-‐25. IF 6.7

22. Janke H, Pastore F, Schumacher D, Herold T, Hopfner KP, Schneider S, Berdel WE, Büchner T, Woermann BJ, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Polzer H.: Activating FLT3 mutants show distinct gain-‐of-‐function phenotypes in vitro and acharacteristic signaling pathway profile associated with prognosis in acute myeloid leukemia. PLoS One. 2014 Mar 7;9(3). IF 4.2

23. Huang Y, Wolf S, Beck B, Köhler LM, Khoury K, Popowicz GM, Goda SK, Subklewe M, Twarda A, Holak TA, Dömling A.: Discovery of Highly Potent p53-‐MDM2 Antagonists and Structural Basis for Anti-‐ Acute Myeloid Leukemia Activities. ACS Chemical Biology 2014 Mar 21;9(3):802-‐11. IF 5.3

24. Krupka C, Bögeholz J, Kischel R, Kufer P, Köhnke T, Lichtenegger F, Schneider S, Metzeler K, Fiegl M, Spiekermann K, Bäuerle P, Zugmaier G, Hiddemann W, Riethmüller G, Subklewe M: CD33 target validation and sustained depletion of AML blasts in long-‐term cultures by the bispecific T-‐cell-‐engaging antibody AMG 330. Blood 2014, Jan 16;123 (3):356-‐65, IF 11.9

25. Anger A, Amache JP, Berninghausen O, Habeck M, Subklewe M, Wilson D, Beckmann R: Structures of the human and Drosophila 80S ribosome. Nature 2013; May 2,497:80-‐85. IF 38.1

26. Lichtenegger F, Schnorfeil F, Hiddemann W, Subklewe M: Current strategies in Immunotherapy for acute myeloid leukemia. Immunotherapy 2013; Jan;5(1):63-‐78. IF 2.1

27. Lichtenegger F, Mueller K, Otte B, Beck B, Hiddemann W, Schendel D.J., Subklewe M: CD86 and IL-‐12p70 Are Key Players for T Helper 1 Polarization and Natural Killer Cell Activation by Toll-‐Like Receptor-‐Induced Dendritic Cells. PLoS One 2012; Sep 4. IF 4.8

28. Walz C, Subklewe M, Horny HP, Flaig M, Reiter A, Kirchner T, Sotlar K: Advanced systemic mastocytosis as a mimicker of metastatic clear cell renal cell carcinoma. Leuk Research 2012, Jun; 36 (6):799-‐801. IF 2.6

29. Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK,


Spiekermann K: Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favourable prognostic factor within NPM1 mutated patients. Ann Hematol 2012, Jul;91(7): 1051-‐1063. IF 3.0

30. Beck B, Dörfel D, Lichtenegger FS, Geiger C, Lindner L, Merk M, Schendel DJ, Subklewe M: Effects of TLR agonists on maturation and function of 3-‐day dendritic cells from AML pateints in complete remision. J Translational Medicine 2011, Sep 13;9:151. IF 3.7

31. Dreyling M, Subklewe M, Braess J, Spiekermann K: Hematology 2010. Dtsch Med. Wochenschrift 2010, Jun; 135 (25-‐26): 1322-‐5. IF 0.5

32. Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jäger E, Mitrou PS: A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubin (Campath-‐FCD) in peripheral T-‐cell lymphomas. Leuk Lymphoma 2010 Mar; 51 (3): 447-‐55. IF 3.1

33. Beigel F, Jürgens M, Tillack C, Subklewe M, Mayr D, Göke B, Brand S, Ochsenkühn T.L: Hepatosplenic T-‐cell lymphoma in a patient with Crohn´s disease. Nat Rev Gastroenterol Hepatol 2009 Jul; 6(7): 433-‐6. IF 14.4

34. Weisel KD, Weidmann E, Anagnostopoulos I, Kanz L., Pezzutto A, Subklewe M: Epstein-‐Barr virus-‐associated B-‐cell lymphoma secondary to FCD-‐C therapy in patients with peripheral T-‐cell lymphoma. Int J Hematol 2008, Nov 88 (4); 434-‐40. IF 1.8

35. Hammer MH, Brestrich G, Mittenzweig A, Roemhild A, Zwinger S, Subklewe M, Beier C, Kurtz A, Babel N, Volk HD, Reinke P: Generation of EBV-‐specific T cells for adoptive immunotherapy: a novel protocol using formalin-‐fixed stimulator cells to increase biosafety. J Immunotherapy 2007 Nov-‐Dec;30 (8):817-‐24, IF 3.7

36. Subklewe M, Anagnostopoulos I: Radiologic and pathologic features of a posttransplantation primary central nervous system lymphoma demonstrating Epstein-‐Barr virus-‐positive Hodgkin lymphoma. Clin Lymphoma Myeloma 2007 Sep; 7(8):535-‐7. IF 2.6

37. Subklewe M, Sebelin-‐Wulf K, Beier C, Lietz A, Mathas S, Dörken B, Pezzutto A: Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Human Immunology 2007, March 68 (3): 147 – 55. IF 2.1

38. Sebelin-‐Wulf, K., Nguyen T D, Oertel S, Papp-‐Vary M, Schulzki A, Trappe R, Pezzutto A, Riess H, Subklewe M: Quantitative analysis of EBV-‐specific CD4 / CD8 T cell numbers, absolute CD4 / CD8 cell numbers and EBV load in solid organ transplant recipients with PTLD. Transplant Immunology 2007, April 17 (3):203-‐10. IF 1.3

39. Subklewe M, Marquis R, Choquet S, Leblond V, Garnier J.L., Hetzer R, Swinnen L, Oertel S, Papp-‐Vary M, Gonzalez-‐Barca E, Hepkema B, Schönemann C, May J, Pezzutto A, Riess H: Association of HLA


haplotypes with PTLD after solid organ transplantation. Transplantation 2006, Oct 27; 82 (8): 1093-‐100. IF 3.7

40. Oertel S, Trappe R.U., Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-‐Vary M, Subklewe M, Dörken B, Riess H, Gartner B: Epstein-‐Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematolgy 2006, 85 (7): 478-‐84. IF 3.0

41. Sebelin K, Schulzki A, Kloetzel P.M., Dörken B, Pezzutto A, Subklewe M: Impairment of circulating myeloid DCs in immunosuppressed renal/pancreas transplant recipients. Transplantation 2006, 82 (6):779-‐787. IF 3.7

42. Subklewe M., Sebelin K., Block A., Meier A., Roukens A., Paludan C., J.F. Fonteneau, Steinman R, Munz C: Dendritic cells expand Epstein Barr Virus specific CD8 T cell responses more efficiently than EBV transformed B cells. Human Immunology 2005; 66: 938-‐949, IF 2.1

43. Subklewe M, Schoch C, Nagy M, Harder L, Jenisch S, Siebert R, Neuhaus P, Dörken B, Schmidt C.A.: Extramedullary manifestation of a donor-‐derived acute myeloid leukemia in a liver transplant patient. Leukemia 2004;18 (12):2050-‐3, IF 12.1

44. Subklewe M.: Dendritic cells for the induction of EBV immunity. Recent Results Cancer Res 2002, 159: 33-‐43.

45. Subklewe M, Paludan C, Tsang L.M, Mahnke K, Steinman R.M, Munz C: Dendritic cells cross-‐present latency gene products from Epstein-‐Barr Virus transformed B cells and expand tumor-‐reactive CD8+ killer T cells. J Exp Med 2001, Feb 5; 193 (3): 405-‐411. IF 14.8

46. Munz C, Bickham K.L, Subklewe M, Tsang M.L, Chahroudi A, Kurilla M, Zhang D, O’Donnell M., Steinman R.M.: Human CD4+ T lymphocytes consistently respond to the latent Epstein-‐Barr virus nuclear antigen EBNA 1. J Exp Med 2000, 191: 1649-‐1660. IF 14.0

47. Subklewe M, Charoudhi A, Schmaljohn A, Kurilla M. G., Bhardwaj N., Steinman R.M.: Induction of Epstein-‐Barr Virus specific CTL responses using dendritic cells pulsed with EBNA-‐3A peptide or UV-‐inactivated, recombinant EBNA-‐3A vaccinia virus. Blood 1999; 4: 1372-‐1381. IF 11.9

48. Subklewe M., Chahroudi A., Bickham K., Larsson M., Kurilla M.G., Bhardwaj N., Steinman R.M.: Presentation of epstein-‐barr virus latency antigens to CD8(+), interferon-‐gamma-‐secreting, T lymphocytes. Eur J Immunol.1999, 29 (12): 3995-‐4001. IF 4.2

49. Engelmayer J., Larsson M., Subklewe M., Chahroudi A., Schmaljohn A., William C., Steinman R.M., Bhardwaj N.: Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol. 1999, 163 (12): 6762-‐8. IF 7.1

50. Inaba K., Turley S., Yamaide F., Iyoda T., Mahnke K., Inaba M., Pack M., Subklewe M., Sauter B., Sheff D., Albert M., Bhardwaj N., Mellman I., and Steinman R.M.: Efficient presentation of


phagocytosed cellular fragments on the MHC class II products of dendritic cells. J Exp. Med. 1998; 188:2163-‐2173. IF 14.3

51. Reddy A., Sapp M., Feldman M., Subklewe M., Bhardwaj N.: A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 1997; 9: 3640 -‐ 3646. IF 9.5

52. Wassermann K., Subklewe M., Pothoff G., Banik N., Schell-‐Frederick E.:Expression of surface markers on alveolar macrophages from symptomatic patients with HIV-‐infection as detected by flow cytometry. Chest 1994; 105: 11324-‐11334. IF 2.3

Book Contributions

1. Hiddemann, contribution Subklewe: “Future outlook for acute leukemia”. Handbook of Acute Leukemia, 2016.

2. Bücklein V, Lichtenegger F, Pfannes K, Götze K, T.Köhnke, Subklewe M: Immunzytologische Untersuchungen bei malignen Lymphomen. Manual Maligne Lymphome, Tumorzentrum München 2015.

3. Waterhouse C, Subklewe M: Akute myeloische Leukämie. Manual Leukämien, myelodysplastische und myeloproliferative Syndrome. Tumorzentrum München 2015.

4. Subklewe M, Bücklein V, Lichtenegger F, Nerl A: Immunzytologische Untersuchungen bei malignen Lymphomen. Manual Maligne Lymphome, Tumorzentrum München 2011.

5. Braess J, Schneider C, Buske C, Spiekermann K, Adorf D., Chrisit O, Heilmeier B., Subklewe M., Schmid C, Fritsch S, Waterhouse C: Akute myeloische Leukämie. Manual Leukämien, myelodysplastische und myeloproliferative Syndrome. Tumorzentrum München 2009.

6. Kanz L., Subklewe M, Brugger W.: High-‐dose chemotherapy requiring cellular support in solid tumors. In: High-‐dose cancer therapy, eds J.O. Armitage and K.H. Antwman, 1996.

SUBKLEWE CV 2016 M4 - EFI...

Documents

Transcript of SUBKLEWE CV 2016 M4 - EFI...